BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses

Grail

Grail

GRAL

0.00

May 30 (Reuters) - Grail Inc GRAL.O:

  • GRAIL REPORTS FULL RESULTS FROM NHS-GALLERI TRIAL DEMONSTRATING SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES AT 2026 ASCO ANNUAL MEETING

  • GRAIL - REPORTS NHS-GALLERI TRIAL SHOWS SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES

  • GRAIL - GALLERI BLOOD TEST REDUCES STAGE IV DIAGNOSES BY 22% IN SECOND AND 26% IN THIRD ROUNDS

  • GRAIL INC - NO REDUCTION OBSERVED IN COMBINED PRIMARY ENDPOINT OF STAGE III/IV CANCERS IN AGGREGATE

Source text: ID:nPn6wRQXma

Further company coverage: GRAL.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.